Pfizer's Second-Generation SARS-CoV-2 Protease Inhibitor
Researchers from Pfizer have developed a structurally-optimized SARS-CoV-2 main protease inhibitor with improved metabolic stability compared to nirmatrelvir which is now in clinical trials.
Jul 27, 2024
Novel remdesivir type nucleoside analogue displays broad-spectrum antiviral activity
The development of a novel 4'-CN remdesivir-type nucleoside analogue demonstrating the potential of 4-aza-7,9-dideazaadenosine nucleoside analogues to exhibit antiviral activity.
Jul 15, 2024
My Reading Tip of the Week: Efficacy of Remdesivir ProDrugs
The efficacy of triphosphate formation of remdesivir is dependent on ProTide substitution. Higher levels of triphosphate in the lung are observed with ProTide prodrugs.
May 24, 2024